An ongoing phase III study (MicroTEC, NCT00908960) in advanced cancer patients with high levels of TF-bearing MVs has been designed to evaluate the benefit of primary thromboprophylaxis and to validate the prognostic usefulness of measuring TF-bearing MVs (6). This evidence concerns the gene TF and cancer.